Literatur
-
1
Anonymous .
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
BMJ.
2002;
324
71-86
-
2
Hayden M, Pignone M, Phillips C, Mulrow C.
Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force.
Ann Intern Med.
2002;
136
161-172
-
3
Garcia-Rodriguez L A, Huerta-Alvarez C.
Reduced risk of colorectal cancer amonglong-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.
Epidemiology.
2001;
12
88-93
-
4
Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, La Vecchia C.
Aspirin use and cancers of the upper aerodigestive tract.
Br J Cancer.
2003;
88
672-674
-
5
Baron J A, Cole B F, Sandler R S, Haile R W, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers R W, Rothstein R, Burke C A, Snover D C, Church T R, Allen J I, Beach M, Beck G J, Bond J H, Byers T, Greenberg E R, Mandel J S, Marcon N, Mott L A, Pearson L, Saibil F, van Stolk R U.
A randomized trial of aspirin to prevent colorectal adenomas.
N Engl J Med.
2003;
348
891-899
-
6
Sandler R S, Halabi S, Baron J A, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas J M, Karp D D, Loprinzi C L, Steinbach G, Schilsky R.
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
N Engl J Med.
2003;
348
883-890
-
7
Vane J R.
Inhibition of prostaglandin synthesis as a mechanism of action for aspirinlike drugs.
Nat New Bio.
1971;
231
232-235
-
8
Thun M J, Henley S J, Patrono C.
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
J Natl Cancer Inst.
2002;
94
252-266
-
9
Chan T A.
Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention.
Lancet Oncol.
2002;
3
166-174
-
10
Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Gastroenterology.
1994;
107
1183-1188
-
11
Ermert L, Dierkes C, Ermert M.
Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
Clin Cancer Res.
2003;
9
1604-1610
-
12
Anderson W F, Umar A, Viner J L, Hawk E T.
The role of cyclooxygenase inhibitors in cancer prevention.
Curr Pharm Des.
2002;
8
1035-1062
-
13
Sheehan K M, Sheahan K, O’Donoghue D P, MacSweeney F, Conroy R M, Fitzgerald D J, Murray F E.
The relationship between cyclooxygenase-2 expression and colorectal cancer.
Jama.
1999;
282
1254-1257
-
14
Steinbach G, Lynch P M, Phillips R K, Wallace M H, Hawk E, Gordon G B, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su L K, Levin B.
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
N Engl J Med.
2000;
342
1946-1952
-
15
Sheng H, Shao J, Washington M K, DuBois R N.
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells.
J Biol Chem.
2001;
276
18075-18081
-
16
Gupta R A, Tan J, Krause W F, Geraci M W, Willson T M, Dey S K, DuBois R N.
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.
Proc Natl Acad Sci USA.
2000;
97
13275-13280
-
17
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois R N.
Cyclooxygenase regulates angiogenesis induced by colon cancer cells.
Cell.
1998;
93
705-716
-
18
Chan T A, Morin P J, Vogelstein B, Kinzler K W.
Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis.
Proc Natl Acad Sci USA.
1998;
95
681-686
-
19
Hannun Y A.
Functions of ceramide in coordinating cellular responses to stress.
Science.
1996;
274
1855-1859
-
20
Scorrano L, Penzo D, Petronilli V, Pagano F, Bernardi P.
Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha aopototic signaling.
J Biol Chem.
2001;
276
12 035-12 040
-
21
Thun M J, Namboodiri M M, Heath C W.
Aspirin use and reduced risk of fatal colon cancer.
N Engl J Med.
1991;
325
1593-1596
-
22
Giovannucci E, Egan K M, Hunter D J, Stampfer M J, Colditz G A, Willett W C, Speizer F E.
Aspirin and the risk of colorectal cancer in women.
N Engl J Med.
1995;
333
609-614
-
23
Meade E A, Smith W L, DeWitt D L.
Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs.
J Biol Chem.
1993;
268
6610-6614
-
24
Patrono C, Patrignani P, Garcia Rodriguez L A.
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
J Clin Invest.
2001;
108
7-13
-
25
Xu X M, Sansores-Garcia L, Chen X M, Matijevic-Aleksic N, Du M, Wu K K.
Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate.
Proc Natl Acad Sci USA.
1999;
96
5292-5297
-
26
Wu J, Xia H H, Tu S P, Fan D M, Lin M C, Kung H F, Lam S K, Wong B C.
15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer.
Carcinogenesis.
2003;
24
243-247
-
27
Grilli M, Pizzi M, Memo M, Spano P.
Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation.
Science.
1996;
274
1383-1385
-
28
He T C, Chan T A, Vogelstein B, Kinzler K W.
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.
Cell.
1999;
99
335-345
-
29
Huls G, Koornstra J J, Kleibeuker J H.
Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.
Lancet.
2003;
362
230-232
-
30
Dihlmann S, Klein S, Doeberitz M K.
Reduction of beta-Catenin/T-Cell Transcription Factor Signaling by Aspirin and Indomethacin Is Caused by an Increased Stabilization of Phosphorylated beta-Catenin.
Mol Cancer Ther.
2003;
2
509-516
-
31
Awtry E H, Loscalzo J.
Aspirin.
Circulation.
2000;
101
1206-1218
-
32
Amann R, Peskar B A.
Anti-inflammatory effects of aspirin and sodium salicylate.
Eur J Pharmacol.
2002;
447
1-9
-
33
Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H O.
Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.
Gastroenterology.
1994;
107
117-120
-
34
Moody G A, Jayanthi V, Probert C S, MacKay H, Mayberry J F.
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.
Eur J Gastroenterol Hepatol.
1996;
8
1179-1183
-
35
Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W.
Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells.
Carcinogenesis.
2003;
24
443-451
-
36
Allgayer H.
Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.
Aliment Pharmacol Ther.
2003;
18
10-14
(Suppl 2)
-
37
Bus P J, Nagtegaal I D, Verspaget H W, Lamers C B, Geldof H, Van Krieken J H, Griffioen G.
Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?.
Aliment Pharmacol Ther.
1999;
13
1397-1402
-
38
Levin B.
Potential pitfalls in the use of surrogate endpoints in colorectal adenoma chemoprevention.
J Natl Cancer Inst.
2003;
95
697-699
-
39
Levi F, Lucchini F, Negri E, La Vecchia C.
Worldwide patterns of cancer mortality 1990 - 94.
Eur J Cancer Prev.
1999;
8
381-400
-
40
Steering Committee of the Physicians’ Health Study Research Group .
Final report on the aspirin component of the ongoing Physicians’ Health Study.
N Engl J Med.
1989;
321
129-135
-
41
Imperiale T F.
Aspirin and the prevention of colorectal cancer.
N Engl J Med.
2003;
348
879-880
-
42
Suleiman S, Rex D K, Sonnenberg A.
Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis.
Gastroenterology.
2002;
122
78-84
-
43
Subbaramaiah K, Hart J C, Norton L, Dannenberg A J.
Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways.
J Biol Chem.
2000;
275
14 838-14 845
-
44
Kune G A, Kune S, Watson L F.
Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.
Cancer Res.
1988;
48
4399-4404
-
45
Rosenberg L, Palmer J R, Zauber A G, Warshauer M E, Stolley P D, Shapiro S.
A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of largebowel cancer.
J Natl Cancer Inst.
1991;
83
355-358
-
46
Suh O, Mettlin C, Petrelli N J.
Aspirin use, cancer, and polyps of the large bowel.
Cancer.
1993;
72
1171-1177
-
47
Muscat J E, Stellman S D, Wynder E L.
Nonsteroidal antiinflammatory drugs and colorectal cancer.
Cancer.
1994;
74
1847-1854
-
48
Peleg I I, Maibach H T, Brown S H, Wilcox C M.
Aspirin and nonsteroidal antiinflammatory drug use and the risk of subsequent colorectal cancer.
Arch Intern Med.
1994;
154
394-399
-
49
Reeves M J, Newcomb P A, Trentham-Dietz A, Storer B E, Remington P L.
Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women.
Cancer Epidemiol Biomarkers Prev.
1996;
5
955-960
-
50
La Vecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, Falcini A, Decarli A.
Aspirin and colorectal cancer.
Br J Cancer.
1997;
76
675-677
-
51
Rosenberg L, Louik C, Shapiro S.
Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma.
Cancer.
1998;
82
2326-2333
-
52
Friedman G D, Coates A O, Potter J D, Slattery M L.
Drugs and colon cancer.
Pharmacoepidemiol Drug Safety.
1998;
7
99-106
-
53
Neugut A I, Rosenberg D J, Ahsan H, Jacobson J S, Wahid N, Hagan M, Rahman M I, Khan Z R, Chen L, Pablos-Mendez A, Shea S.
Association between coronary heart disease and cancers of the breast, prostate, and colon.
Cancer Epidemiol Biomarkers Prev.
1998;
7
869-873
-
54
Paganini-Hill A, Chao A, Ross R K, Henderson B E.
Aspirin use and chronic diseases: a cohort study of the elderly.
Bmj.
1989;
299
1247-1250
-
55
Thun M J, Namboodiri M M, Calle E E, Flanders W D, Heath C W.
Aspirin use and risk of fatal cancer.
Cancer Res.
1993;
53
1322-1327
-
56
Schreinemachers D M, Everson R B.
Aspirin use and lung, colon, and breast cancer incidence in a prospective study.
Epidemiology.
1994;
5
138-146
-
57
Giovannucci E, Rimm E B, Stampfer M J, Colditz G A, Ascherio A, Willett W C.
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.
Ann Intern Med.
1994;
121
241-246
-
58
Bosetti C, Gallus S, La Vecchia C.
Aspirin and cancer risk: an update to 2001.
Eur J Cancer Prev.
2002;
11
535-542
-
59
Harris R E, Namboodiri K K, Farrar W B.
Nonsteroidal antiinflammatory drugs and breast cancer.
Epidemiology.
1996;
7
203-205
-
60
Coogan P F, Rao S R, Rosenberg L, Palmer J R, Strom B L, Zauber A G, Stolley P D, Shapiro S.
The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer.
Prev Med.
1999;
29
72-76
-
61
Friedman G D, Ury H K.
Initial screening for carcinogenicity of commonly used drugs.
J Natl Cancer Inst.
1980;
65
723-733
-
62
Egan K M, Stampfer M J, Giovannucci E, Rosner B A, Colditz G A.
Prospective study of regular aspirin use and the risk of breast cancer.
J Natl Cancer Inst.
1996;
88
988-993
-
63
Harris R E, Kasbari S, Farrar W B.
Prospective study of nonsteoridal antiinflammatory drugs and breast cancer.
Oncol Rep.
1999;
6
71-73
-
64
Tzonou A, Polychronopoulou A, Hsieh C C, Rebelakos A, Karakatsani A, Trichopoulos D.
Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer.
Int J Cancer.
1993;
55
408-410
-
65
Cramer D W, Harlow B L, Titus-Ernstoff L, Bohlke K, Welch W R, Greenberg E R.
Over-the-counter analgesics and risk of ovarian cancer.
Lancet.
1998;
351
104-107
-
66
Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S.
Aspirin and ovarian cancer: an Italian case-control study.
Ann Oncol.
2000;
11
1171-1173
-
67
Rosenberg L, Palmer J R, Rao R S, Coogan P F, Strom B L, Zauber A G, Stolley P D, Shapiro S.
A case-control study of analgesic use and ovarian cancer.
Cancer Epidemiol Biomarkers Prev.
2000;
9
933-937
-
68
Moysich K B, Mettlin C, Piver M S, Natarajan N, Menezes R J, Swede H.
Regular use of analgesic drugs and ovarian cancer risk.
Cancer Epidemiol Biomarkers Prev.
2001;
10
903-906
-
69
Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig K L, Shore R E.
Aspirin and epithelial ovarian cancer.
Prev Med.
2001;
33
682-687
-
70
Leitzmann M F, Stampfer M J, Ma J, Chan J M, Colditz G A, Willett W C, Giovannucci E.
Aspirin use in relation to risk of prostate cancer.
Cancer Epidemiol Biomarkers Prev.
2002;
11
1108-1111
-
71
Farrow D C, Vaughan T L, Hansten P D, Stanford J L, Risch H A, Gammon M D, Chow W H, Dubrow R, Ahsan H, Mayne S T, Schoenberg J B, West A B, Rotterdam H, Fraumeni J F, Blot W J.
Use of aspirin and other 10 nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.
Cancer Epidemiol Biomarkers Prev.
1998;
7
97-102
-
72
Sharp L, Chilvers C E, Cheng K K, McKinney P A, Logan R F, Cook-Mozaffari P, Ahmed A, Day N E.
Risk factors for squamous cell carcinoma of the oesophagus in women: a case-control study.
Br J Cancer.
2001;
85
1667-1670
-
73
Funkhouser E M, Sharp G B.
Aspirin and reduced risk of esophageal carcinoma.
Cancer.
1995;
76
1116-1119
-
74
Akre K, Ekstrom A M, Signorello L B, Hansson L E, Nyren O.
Aspirin and risk for gastric cancer: a population-based case-control study in Sweden.
Br J Cancer.
2001;
84
965-968
-
75
Anderson K E, Johnson T W, Lazovich D, Folsom A R.
Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer.
J Natl Cancer Inst.
2002;
94
1168-1171
Dr. Dirk Taubert
Gleueler Str. 24
50931 Köln
Phone: 0221-4784196
Fax: 0221-4785022
Email: dirk.taubert@medizin.uni-koeln.de
